MM-CARE: Cardiovascular Risk Assessment in Adults With Multiple Myeloma
for Multiple Myeloma
1 location in Burlington
Sponsor: University of Vermont Medical Center
Sex: All·Age: 18+
Code: NCT07783607·Not Yet Recruiting·Listed Aug 25, 2026
Clinical Trials at University of Vermont Medical Center
As of September 2026, 69 paid clinical trials are recruiting at University of Vermont Medical Center, located at 111 COLCHESTER AVE, BURLINGTON, VT 05401-1473, phone (802) 847-9852 in Burlington, Vermont. Active studies at this site cover conditions such as Heart Failure, Acute Myeloid Leukemia and Anatomic Stage II Breast Cancer AJCC v8. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
Filter results
Newly added in Burlington
Posted to ClinicalTrials.gov within the last 60 days — these studies are just starting to recruit.
Shortening Radiation Course Duration Using Simultaneous Integrated Boost With Lower Intensity Elective Nodal Dosing and Concurrent Chemotherapy for High-Risk Anal Squamous Cell Carcinoma
for Anal Cancer
1 location in Burlington
Sponsor: University of Vermont Medical Center
Sex: All·Age: 18+
Code: NCT07775209·Phase 2·Enrolling By Invitation·Listed Aug 20, 2026
71 clinical trials at University of Vermont Medical Center
·Clear filters· Get a weekly email when new trials open in Burlington, VT.
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
for Breast Cancer
Sites in Burlington +171 more locations
Sponsor: Stemline Therapeutics, Inc.
Sex: All·Age: 18+
Code: NCT06492616·Phase 3·Recruiting·Listed Jul 2024
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
for Parkinson's Disease
Drug: Prasinezumab
Sites in Burlington +52 more locations
Sponsor: Hoffmann-La Roche
Sex: All·Age: 50 - 85
Code: NCT07174310·Phase 3·Recruiting·Listed Sep 2025
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
for Urinary Bladder Neoplasms
Sites in Burlington +40 more locations
Sponsor: Eli Lilly and Company
Sex: All·Age: 18+
Code: NCT05614739·Phase 1·Recruiting·Listed Nov 2022
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
for Chronic Inflammatory Demyelinating Polyneuropathy
Drug: riliprubart
Sites in Burlington +31 more locations
Sponsor: Sanofi
Sex: All·Age: 18+
Code: NCT06290141·Phase 3·Recruiting·Listed Mar 2024
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
for Acute Myeloid Leukemia (AML)
Sites in Burlington +41 more locations
Sponsor: Kura Oncology, Inc.
Sex: All·Age: 18+
Code: NCT07007312·Phase 3·Recruiting·Listed Jun 2025
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
for Advanced Melanoma
Drug: Nivolumab
Sites in Burlington +43 more locations
Sponsor: Replimune, Inc.
Sex: All·Age: 12+
Code: NCT06264180·Phase 3·Recruiting·Listed Feb 2024
A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease
for Parkinsons Disease (PD)
Sites in Burlington +33 more locations
Sponsor: BlueRock Therapeutics
Sex: All·Age: 45 - 75
Code: NCT06944522·Phase 3·Recruiting·Listed Apr 2025
REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE
for Aortic Stenosis
Sites in Burlington +70 more locations
Sponsor: Medtronic Cardiovascular
Sex: All·Age: 18 - 105
Code: NCT06777368·Recruiting·Listed Jan 2025
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
for Carcinoma, Non-Small-Cell Lung
Sites in Burlington +17 more locations
Sponsor: Johnson & Johnson Enterprise Innovation Inc.
Sex: All·Age: 18+
Code: NCT06667908·Phase 2·Recruiting·Listed Oct 2024
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
for Crohn's Disease
Sites in Burlington +14 more locations
Sponsor: Eli Lilly and Company
Sex: All·Age: 2 - 17
Code: NCT05509777·Phase 3·Recruiting·Listed Aug 2022
An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis
for Recurrent Pericarditis
Drug: VTX2735
Sites in Burlington +14 more locations
Sponsor: Zomagen Biosciences Ltd.
Sex: All·Age: 18 - 75
Code: NCT06836232·Phase 2·Recruiting·Listed Feb 2025
Endocardial Mapping With the CoreMap EP Mapping System
for Persistent Atrial Fibrillation
Sites in Burlington +2 more locations
Sponsor: CoreMap Inc.
Sex: All·Age: 18 - 80
Code: NCT06529978·Recruiting·Listed Jul 2024
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
for Breast Cancer
Sites in Burlington, Berlin Corners +1087 more locations
Sponsor: NRG Oncology
Sex: Female·Age: 18 - 60
Code: NCT05879926·Phase 3·Recruiting·Listed May 2023
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
for Stage III Colon Cancer
Sites in Burlington, Saint Johnsbury +923 more locations
Sponsor: NRG Oncology
Sex: All·Age: 18+
Code: NCT05174169·Phase 2, Phase 3·Recruiting·Listed Dec 2021
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
for Intracranial Meningioma
Sites in Burlington, Saint Johnsbury +446 more locations
Sponsor: Alliance for Clinical Trials in Oncology
Sex: All·Age: 18+
Code: NCT02523014·Phase 2·Recruiting·Listed Aug 2015
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
for Advanced Esophageal Adenocarcinoma
Drug: Nivolumab
Sites in Burlington, Berlin Corners +626 more locations
Sponsor: Alliance for Clinical Trials in Oncology
Sex: All·Age: 18+
Code: NCT05677490·Phase 3·Recruiting·Listed Jan 2023
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
for Anatomic Stage I Breast Cancer AJCC v8
Sites in Burlington, Saint Johnsbury +594 more locations
Sponsor: Alliance for Clinical Trials in Oncology
Sex: All·Age: 18+
Code: NCT06876714·Phase 3·Recruiting·Listed Mar 2025
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
for Plasma Cell Myeloma
Sites in Burlington, White River Junction +303 more locations
Sponsor: ECOG-ACRIN Cancer Research Group
Sex: All·Age: 18+
Code: NCT04566328·Phase 3·Recruiting·Listed Sep 2020
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
for Metastatic Renal Cell Carcinoma
Sites in Burlington, Berlin Corners +278 more locations
Sponsor: NRG Oncology
Sex: All·Age: 18+
Code: NCT05327686·Phase 2·Recruiting·Listed Apr 2022
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
for Pancreatic Neoplasm
Sites in Burlington, Berlin Corners +333 more locations
Sponsor: ECOG-ACRIN Cancer Research Group
Sex: All·Age: 50 - 75
Code: NCT04239573·Recruiting·Listed Jan 2020
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
for Muscle Invasive Bladder Urothelial Carcinoma
Sites in Burlington, Berlin Corners +441 more locations
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 18+
Code: NCT05987241·Phase 2, Phase 3·Recruiting·Listed Aug 2023
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
for Clear Cell Renal Cell Carcinoma
Sites in Burlington, Berlin Corners +401 more locations
Sponsor: Alliance for Clinical Trials in Oncology
Sex: All·Age: 18+
Code: NCT06661720·Phase 3·Recruiting·Listed Oct 2024
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
for Anatomic Stage II Breast Cancer AJCC v8
Sites in Burlington, Berlin Corners +777 more locations
Sponsor: Alliance for Clinical Trials in Oncology
Sex: All·Age: 18+
Code: NCT05812807·Phase 3·Recruiting·Listed Apr 2023
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
for Astrocytoma, IDH-Mutant, Grade 3
Drug: Vorasidenib
Sites in Burlington +116 more locations
Sponsor: Alliance for Clinical Trials in Oncology
Sex: All·Age: 12+
Code: NCT07215910·Phase 3·Recruiting·Listed Oct 2025
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
for Acute Myeloid Leukemia
Sites in Burlington +325 more locations
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 18+
Code: NCT05564390·Phase 2·Recruiting·Listed Oct 2022
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
for Acute Myeloid Leukemia
Sites in Burlington +204 more locations
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 18 - 59
Code: NCT05554406·Phase 2·Recruiting·Listed Sep 2022
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
for Acute Myeloid Leukemia
Drug: Venetoclax
Sites in Burlington +212 more locations
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 18+
Code: NCT06317649·Phase 2·Recruiting·Listed Mar 2024
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
for Acute Myeloid Leukemia
Drug: Venetoclax
Sites in Burlington +166 more locations
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 18 - 59
Code: NCT05554393·Phase 2·Recruiting·Listed Sep 2022
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
for Childhood Extracranial Germ Cell Tumor
Sites in Burlington +381 more locations
Sponsor: Children's Oncology Group
Sex: All·Age: All ages
Code: NCT03067181·Phase 3·Recruiting·Listed Mar 2017
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
for Locally Advanced Lung Non-Small Cell Carcinoma
Sites in Burlington, Saint Johnsbury +444 more locations
Sponsor: NRG Oncology
Sex: All·Age: 18+
Code: NCT05624996·Phase 3·Recruiting·Listed Nov 2022
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
for Locally Advanced Urothelial Carcinoma
Sites in Burlington, Berlin Corners +157 more locations
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 18+
Code: NCT06524544·Phase 3·Recruiting·Listed Jul 2024
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
for Prostate Adenocarcinoma
Sites in Burlington, Saint Johnsbury +397 more locations
Sponsor: NRG Oncology
Sex: Male·Age: 18+
Code: NCT05946213·Phase 3·Recruiting·Listed Jul 2023
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
for Non-Muscle Invasive Bladder Urothelial Carcinoma
Sites in Burlington, Berlin Corners +133 more locations
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 18+
Code: NCT06770582·Phase 2·Recruiting·Listed Jan 2025
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
for Castration-Sensitive Prostate Carcinoma
Drug: Apalutamide
Sites in Burlington, Berlin Corners +203 more locations
Sponsor: Alliance for Clinical Trials in Oncology
Sex: Male·Age: 18+
Code: NCT06931340·Phase 3·Recruiting·Listed Apr 2025
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
for Retroperitoneal Sarcoma
Sites in Burlington +101 more locations
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Sex: All·Age: 18+
Code: NCT04031677·Phase 3·Recruiting·Listed Jul 2019
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
for Endometrial Cancer
Sites in Burlington +76 more locations
Sponsor: Canadian Cancer Trials Group
Sex: Female·Age: 18+
Code: NCT05640999·Phase 2·Recruiting·Listed Dec 2022
Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy
for Peripartum Cardiomyopathy, Postpartum
Sites in Burlington +60 more locations
Sponsor: Dennis M. McNamara, MD, MS
Sex: Female·Age: 18+
Code: NCT05180773·Phase 4·Recruiting·Listed Jan 2022
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
for Buccal Mucosa Squamous Cell Carcinoma
Sites in Burlington, Berlin Corners +85 more locations
Sponsor: NRG Oncology
Sex: All·Age: 18+
Code: NCT04333537·Phase 2, Phase 3·Recruiting·Listed Apr 2020
Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma
for Glioblastoma
Sites in Burlington +10 more locations
Sponsor: Memorial Sloan Kettering Cancer Center
Sex: All·Age: 18+
Code: NCT06934889·Phase 1·Recruiting·Listed Apr 2025
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
for Previously Treated Non-Small Cell Lung Cancer
Sites in Burlington, Saint Johnsbury +948 more locations
Sponsor: SWOG Cancer Research Network
Sex: All·Age: 18+
Code: NCT03851445·Phase 2, Phase 3·Recruiting·Listed Feb 2019
Common conditions studied in Burlington
- Heart Failure (7 active studies)
- Acute Myeloid Leukemia (6 active studies)
- Anatomic Stage II Breast Cancer AJCC v8 (3 active studies)
- Breast Cancer (3 active studies)
- Cancer (3 active studies)
- Carcinoma, Non-Small-Cell Lung (3 active studies)
Leading research sponsors in Burlington
- University of Vermont
- University of Vermont Medical Center
- National Cancer Institute (NCI)
- Children's Oncology Group
- Alliance for Clinical Trials in Oncology
Frequently asked questions
How many paid clinical trials are currently recruiting in Burlington?
There are approximately 160 recruiting clinical trials in Burlington, Vermont listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Burlington pay participants?
Most recruiting trials in Burlington compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Burlington?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Burlington?
The most common conditions under active study in Burlington include Heart Failure (7), Acute Myeloid Leukemia (6), Anatomic Stage II Breast Cancer AJCC v8 (3), Breast Cancer (3), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Burlington?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Burlington on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Burlington?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Burlington?
Recruiting research sites in Burlington include University of Vermont Medical Center, University of Vermont and State Agricultural College, University of Vermont, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Burlington right now?
The largest active categories in Burlington are Cancer & tumors (67), Cardiovascular (17), Neurology & pain (5). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of University of Vermont Medical Center?
University of Vermont Medical Center is located at 111 COLCHESTER AVE, BURLINGTON, VT 05401-1473. Use the Google Maps link in the intro above to get directions.
How do I contact University of Vermont Medical Center?
You can reach University of Vermont Medical Center by phone at (802) 847-9852. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.